Publications 1999

  1. Chojnacka-Wójcik, E.; Kłodzińska, A.; Tatarczyńska, E.; Paluchowska, M. H. Some pharmacological properties of new analogs of MP 3022, the 5-HT1A receptor antagonist. Pol. J. Pharmacol. 1999, 51, 405-413 (http://www.ncbi.nlm.nih.gov/pubmed/10817541).
  2. Paluchowska, M. H.; Mokrosz, M. J. ; Bojarski, A. J.; Wesołowska, A.; Borycz, J.; Charakchieva-Minol, S.; Chojnacka-Wójcik, E. On the bioactive conformation of NAN-190 (1) and MP3022 (2), 5-HT(1A) receptor antagonists. J. Med. Chem. 1999, 42, 4952-4960 (http://www.ncbi.nlm.nih.gov/pubmed/10585205).
  3. Bojarski, A. J.; Mokrosz, M. J. 1,2,3,4-Tetrahydroisoquinoline derivatives; lipophilicity evaluation vs. 5-HT1A receptor affinity. Pharmazie 1999, 54, 828-830 (http://www.ncbi.nlm.nih.gov/pubmed/10603608).
  4. Mokrosz, M. J.; Kowalski, P.; Kowalska, T.; Majka, Z.; Duszyńska, B.; Bojarski, A. J.; Fruziński, A.; Karolak-Wojciechowska, J.; Wesołowska, A.; Kłodzińska, A.; Tatarczyńska, E.; Chojnacka-Wójcik, E. Structure-activity relationship studies of CNS agents. Part 38. Novel 1,4-benzoxazin-3(4H)-one, 1,2-benzoxazolin-3-one and 1,3-benzoxazolin-2,4-dione arylpiperazine derivatives with different 5-HT1A and antagonistic 5-HT2A activities. Arch. Pharm. (Weinheim) 1999, 332, 373-379 (http://www.ncbi.nlm.nih.gov/pubmed/10605377).
  5. Paluchowska, M. H.; Charakchieva-Minol, S.; Tatarczyńska, E.; Kłodzińska, A. Effect of the amide fragment on 5-HT1A receptor activity of some analogs of MP 3022 . Pol. J. Pharmacol. 1999, 51, 415-421 (http://www.ncbi.nlm.nih.gov/pubmed/10817542).
  6. Mokrosz, M. J.; Boksa, J.; Charakchieva-Minol, S.; Wesołowska, A.; Borycz, J. 9-Substituted 1,2,3,4-tetrahydro-β-carbolin-1-ones, new 5-HT1A and 5-HT2A receptor ligands. Pol. J. Pharmacol. 1999, 51, 351-356 (http://www.ncbi.nlm.nih.gov/pubmed/10540967).
  7. Pawłowski, M.; Katlabi, J.; Drabczyńska, A.; Duszyńska, B.; Charakchieva-Minol, S.; Dereń-Wesołek, A.; Tatarczyńska, E.; Chojnacka-Wójcik, E.; Mokrosz, M. J. ; Bojarski, A. J. New 9- or 10-arylpiperazinoalkyl substituted pyrimido- or diazepino[2,1-f]purines with partial or full 5-HT1A agonistic activity. Eur. J. Med. Chem. 1999, 34, 167-175 (http://www.sciencedirect.com/science/article/pii/S0223523499800506).
  8. Strekowski, L.; Zegrocka, O.; Henary, M.; Say, M.; Mokrosz, M. J.; Kotecka, B. M.; Manzel, L.; Macfarlane, D. E. Structure-activity relationship analysis of substituted 4-quinolinamines, antagonists of immunostimulatory CpG-oligodeoxynucleotides. Bioorg. Med. Chem. Lett. 1999, 9, 1819-1824 (http://www.ncbi.nlm.nih.gov/pubmed/10406648).
  9. Mokrosz, M. J.; Bojarski, A. J.; Duszyńska, B.; Tatarczyńska, E.; Kłodzińska, A.; Dereń-Wesołek, A.; Charakchieva-Minol, S.; Chojnacka-Wójcik, E. 1,2,3,4-Tetrahydroisoquinoline derivatives: a new class of 5-HT1A receptor ligands. Bioorg. Med. Chem. 1999, 7, 287-295 (http://www.ncbi.nlm.nih.gov/pubmed/10218820).
  10. Ryng, S.; Zimecki, M.; Sonnenberg, Z.; Mokrosz, M. J. Immunomodulating action and structure-activity relationships of substituted phenylamides of 5-amino-3-methylisoxazole-4-carboxylic acid. Arch. Pharm. (Weinheim) 1999, 332, 158-162 (http://www.ncbi.nlm.nih.gov/pubmed/10366900).